MedPath

Hybrid Training and Middle Age

Not Applicable
Completed
Conditions
Middle Aged
Non-alcoholic Fatty Liver Disease
Women's Health
Hybrid Training
Metabolic Syndrome
Interventions
Other: hybrid training
Registration Number
NCT05231564
Lead Sponsor
University of Sistan and Baluchestan
Brief Summary

Modern living and physical inactivity results in many ailments, including obesity, non-alcoholic fatty liver disease (NAFLD), and inflammatory issues.

Though there are a lot of studies on physical training, there is little detail on hybrid training or electrical and voluntary contractions of the musculature. This study investigated the efficiency of hybrid training in biochemistry, ultrasound, and proinflammatory outcomes in middle-aged sedentary and obese women with NAFLD.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
15
Inclusion Criteria
  • Sedentary women with one to two exercise sessions or less per month
  • BMI equal to or above 30 kg/m-2
  • WHR equal or above 0.85 m
  • Confirmed NAFLD, with grade 2 and 3
  • Systolic blood pressure not less than 130 mm Hg and diastolic blood pressure not less than 85 mm Hg
  • Increased AST and ALT
  • Mean age 45-65 years
Exclusion Criteria
  • Use of 140 grams or more of ethanol per week
  • History of depression in the last 6 months
  • History of chronic or acute viral hepatitis
  • Drug-related liver disease and chronic liver disease
  • History of diabetes
  • Uncontrolled hypertension
  • Myocardial infarction
  • Chronic kidney disease
  • Hyperthyroidism or heart failure
  • Those who have weight loss programs or medical contraindications for physical training
  • Serious arterial hemorrhagic disorders
  • Serious neurological diseases
  • Advanced atherosclerosis
  • Elevated fever

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Hybrid traininghybrid training15 women for hybrid training.
Primary Outcome Measures
NameTimeMethod
Alanine transaminasesPre-study

in u/l

Body WeightPre-study

in kg

Body Mass IndexPre-study

in kg/m-2

Aspartate transaminasesPre-study

in u/l

Fasting blood sugarPre-study

in mg/dl

Proinflammatory cytokine (interleukin -6)Pre-study

in pg/ml

Ultrasonic assessmentPre-study

Grade of liver steatosis

WHRPre-study

Waist-to-hip ratio in cm

SBP/DBPPre-study

Systolic blood pressure/Diastolic blood pressure

HDL Cholesterol PlasmaPre-study

in mg/dl

Secondary Outcome Measures
NameTimeMethod
Body Weightsix-week

in kg

HDL Cholesterol Plasmasix-week

in mg/dl

Body Mass Indexsix-week

in kg/m-2

Aspartate transaminasessix-week

in u/l

Alanine transaminasessix-week

in u/l

Fasting blood sugarsix-week

in mg/dl

Proinflammatory cytokine (interleukin -6)six-week

in pg/ml

Ultrasonic assessmentsix-week

Grade of liver steatosis

WHRsix-week

Waist-to-hip ratio in cm

SBP/DBPsix-week

Systolic blood pressure/Diastolic blood pressure

Trial Locations

Locations (1)

Mohammadreza Rezaeipour (MD, PhD)

🇮🇷

Zahedan, Sistan And Baluchestan, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath